CoreAge Rx vs VyrarX
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and VyrarX head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 66 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make VyrarX a bad call — it's best for readers seeking online clinician messaging who will obtain the medication, pharmacy and payment details before choosing a plan. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | VyrarX |
|---|---|---|
| Brief Score | 94/100 (A) | 66/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Confirm prescription and full charge Semaglutide advertised from $179/month; exact formulation, supplied quantity and fee breakdown unconfirmed. Terms exclude California, South Carolina and New Jersey; individual eligibility applies. Full price detailsSemaglutide offered; formulation and complete selected-plan quote unknown; homepage advertises weekly injections from $179/month without supplied quantity or full fee breakdown |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Confirm prescription and full charge Tirzepatide advertised from $329/month; exact formulation, supplied quantity and fee breakdown unconfirmed. Unused subscription periods generally are not refundable; confirm the prescription-order status. Full price detailsTirzepatide offered; formulation and complete selected-plan quote unknown; homepage advertises from $329/month without supplied quantity or full fee breakdown |
| Coverage | US only; restrictions by state, confirmed at intake | Terms exclude California, South Carolina and New Jersey; individual clinical eligibility still applies |
| Brand-name access | Not confirmed | A current branded GLP-1 offer was not established; the exact prescription remains unconfirmed. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
VyrarX: Semaglutide from $179/month and tirzepatide from $329/month are starting advertisements; confirm the full selected supply, formulation and charge.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.